1. Home
  2. BEEM vs TVRD Comparison

BEEM vs TVRD Comparison

Compare BEEM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Global

BEEM

Beam Global

HOLD

Current Price

$1.13

Market Cap

28.6M

Sector

Technology

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$1.29

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEEM
TVRD
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6M
27.5M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
BEEM
TVRD
Price
$1.13
$1.29
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$3.50
★ $29.50
AVG Volume (30 Days)
★ 294.4K
189.8K
Earning Date
04-09-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
40.77
★ 79.01
EPS
N/A
★ N/A
Revenue
★ $28,236,000.00
$911,000.00
Revenue This Year
$40.48
N/A
Revenue Next Year
$32.17
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 959.30
52 Week Low
$0.97
$0.93
52 Week High
$4.04
$43.65

Technical Indicators

Market Signals
Indicator
BEEM
TVRD
Relative Strength Index (RSI) 34.20 34.74
Support Level $1.09 N/A
Resistance Level $1.66 $2.02
Average True Range (ATR) 0.06 0.16
MACD -0.03 -0.03
Stochastic Oscillator 1.52 35.51

Price Performance

Historical Comparison
BEEM
TVRD

About BEEM Beam Global

Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: